MANNATECH INC
MTEXNasdaqHealthcare · Medicinal Chemicals & Botanical Products · TX · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $108.0M | $117.9M | $132.0M | $137.2M | $159.8M | $151.4M |
| Operating income | −$426,000 | $1.4M | −$964,000 | −$405,000 | $9.0M | $4.5M |
| Net income | −$15.2M | $2.5M | −$2.2M | −$4.5M | $9.8M | $6.3M |
| Total assets | $30.0M | $36.1M | $41.2M | $49.1M | $59.6M | $65.3M |
| Total liabilities | $35.2M | $27.4M | $30.7M | $35.0M | $35.2M | $39.4M |
| Equity | −$5.2M | $8.6M | $10.5M | $14.2M | $24.4M | $26.0M |
| EPS (diluted) | $-8.00 | $1.32 | $-1.20 | $-2.35 | $4.71 | $2.77 |
| Shares out. | 1.9M | 1.9M | 1.9M | 2.1M | 2.1M | 2.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −0.4%
- Net margin
- −14.1%
- Return on equity
- 291.3%
- Return on assets
- −50.7%
- Return on capital (ROCE)
- −3.8%
- Liabilities / assets
- 117.4%
- Debt / equity
- —
- Book value / share
- $-2.75
- Revenue growth (YoY)
- −8.3%
- Net income growth (YoY)
- −711.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.37distress
- Accruals / assets
- −40.8%clean
- Beneish M-Score
- -5.41normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-K/Amissed a reporting deadline ↗Apr 2, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Kmissed a reporting deadline ↗Mar 17, 2005
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Toth RobertActivist (13D)Apr 24, 2026
- Lacore TerryPassive (13G)Jan 24, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jobe Larry ADirector | May 20, 2026 | Buy | 2,803 | $4.12 |
| Jobe Larry ADirector | May 19, 2026 | Buy | 5,000 | $4.20 |
| Robbins Kevin AndrewDirector | May 19, 2026 | Buy | 7,100 | $4.17 |
| Jobe Larry ADirector | Jan 2, 2026 | Grant | 4,790 | $8.35 |
| Robbins Kevin AndrewDirector | Jan 2, 2026 | Grant | 4,790 | $8.35 |
| John Seifrick ADirector | Jan 2, 2026 | Grant | 4,790 | $8.35 |
| Toth RobertDirector | Jan 2, 2026 | Grant | 4,790 | $8.35 |
| Fredrick J StanleyDirector | Jan 2, 2026 | Grant | 4,790 | $8.35 |
| Rameson TylerDirector | Jan 2, 2026 | Grant | 4,790 | $8.35 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 41,501 | 1.0 | +62.2% |
| Apr 30, 2026 | 25,588 | 5.7 | -2.6% |
| Apr 15, 2026 | 26,281 | 1.0 | +120.6% |
| Mar 31, 2026 | 11,912 | 3.5 | +4.0% |
| Mar 13, 2026 | 11,458 | 3.6 | -9.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Delisting / listing-standard noticeApr 24, 2026
- Results of operationsApr 15, 2026
- Other material eventApr 2, 2026
- Director / officer changeMar 24, 2026
- Results of operationsNov 12, 2025
- Entered a material agreementSep 12, 2025
- Director / officer changeJul 24, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4FORM 4May 21, 2026
- 4FORM 4May 20, 2026
- 4FORM 4May 20, 2026
- 8-KFORM 8-KMay 14, 2026
- 10-QFORM 10-QMay 14, 2026
- 8-KFORM 8-KApr 24, 2026
- SCHEDULE 13DApr 24, 2026
- DEFA14AFORM DEFA14AApr 21, 2026
- DEF 14AFORM DEF 14AApr 21, 2026
- 8-KFORM 8-KApr 15, 2026
- 10-KFORM 10-KApr 15, 2026
- NT 10-K/AFORM NT 10-K/AApr 2, 2026
- 8-KFORM 8-KApr 2, 2026
- NT 10-KFORM NT 10-KApr 1, 2026
- 8-KFORM 8-KMar 24, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.